Daniel L. Azarnoff

7.0k total citations · 1 hit paper
132 papers, 5.7k citations indexed

About

Daniel L. Azarnoff is a scholar working on Pharmacology, Molecular Biology and Pharmacology. According to data from OpenAlex, Daniel L. Azarnoff has authored 132 papers receiving a total of 5.7k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Pharmacology, 21 papers in Molecular Biology and 17 papers in Pharmacology. Recurrent topics in Daniel L. Azarnoff's work include Pharmacogenetics and Drug Metabolism (18 papers), Metabolism and Genetic Disorders (11 papers) and Analytical Methods in Pharmaceuticals (11 papers). Daniel L. Azarnoff is often cited by papers focused on Pharmacogenetics and Drug Metabolism (18 papers), Metabolism and Genetic Disorders (11 papers) and Analytical Methods in Pharmaceuticals (11 papers). Daniel L. Azarnoff collaborates with scholars based in United States, Sweden and Germany. Daniel L. Azarnoff's co-authors include Charles E. Hignite, Janardan K. Reddy, Donald J. Svoboda, David H. Huffman, Don W. Shoeman, Danny D. Shen, Suk Han Wan, R Gugler, Folke Sjöqvist and Harold Grady and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Daniel L. Azarnoff

129 papers receiving 5.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens

1980 740 citations Janardan K. Reddy, Daniel L. Azarnoff et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel L. Azarnoff United States	40	2.0k	971	831	720	651	132	5.7k
Paul Hochstein United States	49	4.4k 2.2×	730 0.8×	498 0.6×	401 0.6×	374 0.6×	111	10.9k
M.W. Anders United States	45	4.3k 2.2×	1.7k 1.7×	815 1.0×	420 0.6×	451 0.7×	173	8.9k
William Bosron United States	50	2.8k 1.4×	980 1.0×	533 0.6×	322 0.4×	1.4k 2.1×	105	7.4k
Peter Moldéus Sweden	53	3.4k 1.7×	2.5k 2.6×	1.1k 1.4×	438 0.6×	527 0.8×	221	9.7k
Kevin H. Cheeseman United Kingdom	30	2.4k 1.2×	660 0.7×	312 0.4×	463 0.6×	393 0.6×	67	9.0k
Marcus M. Reidenberg United States	41	1.0k 0.5×	710 0.7×	480 0.6×	194 0.3×	625 1.0×	140	4.9k
Mario Comporti Italy	48	2.6k 1.3×	876 0.9×	337 0.4×	281 0.4×	237 0.4×	144	7.7k
Jerry B. Hook United States	36	974 0.5×	1.3k 1.3×	806 1.0×	241 0.3×	436 0.7×	216	4.2k
Russell A. Prough United States	49	2.9k 1.4×	2.5k 2.6×	1.1k 1.3×	273 0.4×	476 0.7×	199	7.7k
A.E.M. McLean United Kingdom	34	1.3k 0.7×	1.2k 1.2×	520 0.6×	285 0.4×	154 0.2×	128	3.9k

Countries citing papers authored by Daniel L. Azarnoff

Since Specialization

Citations

This map shows the geographic impact of Daniel L. Azarnoff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel L. Azarnoff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel L. Azarnoff more than expected).

Fields of papers citing papers by Daniel L. Azarnoff

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel L. Azarnoff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel L. Azarnoff. The network helps show where Daniel L. Azarnoff may publish in the future.

Co-authorship network of co-authors of Daniel L. Azarnoff

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel L. Azarnoff. A scholar is included among the top collaborators of Daniel L. Azarnoff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel L. Azarnoff. Daniel L. Azarnoff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Azarnoff, Daniel L., et al.. (2007). Quality of Extemporaneously Compounded Nitroglycerin Ointment. Diseases of the Colon & Rectum. 50(4). 509–516. 10 indexed citations

Gibbons, Robert D., Byron W. Brown, Daniel L. Azarnoff, et al.. (1999). Assessment of the Safety and Efficacy Data for the Hypnotic Halcion^(R): Results of an Analysis by an Institute of Medicine Committee. Journal of the American Statistical Association. 94(448). 993–1002. 1 indexed citations

Abernethy, D R & Daniel L. Azarnoff. (1990). Pharmacokinetic Investigations in Elderly Patients. Clinical Pharmacokinetics. 19(2). 89–93. 13 indexed citations

Huffman, David H., et al.. (1980). The effect of concurrent oral administration of propranolol and disopyramide on cardiac function in healthy men.. Circulation. 61(5). 938–945. 24 indexed citations

Azarnoff, Daniel L.. (1979). The Role of the Clinical Pharmacologist in the Practice of Medicine. Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics. 10(1). 133–136.

Carruthers, S. George, Don W. Shoeman, Charles E. Hignite, & Daniel L. Azarnoff. (1979). Correlation between Plasma Diphenhydramine Level and Sedative and Antihistamine Effects. Survey of Anesthesiology. 23(2). 86–86. 3 indexed citations

Azarnoff, Daniel L., et al.. (1979). Metabolic responses to plasma concentrations of theophylline. Clinical Pharmacology & Therapeutics. 26(1). 89–95. 15 indexed citations

Huffman, David H., Jens P. Kampmann, Charles E. Hignite, & Daniel L. Azarnoff. (1978). Gynecomastia induced in normal males by spironolactone. Clinical Pharmacology & Therapeutics. 24(4). 465–473. 32 indexed citations

Reddy, Janardan K., David E. Moody, Daniel L. Azarnoff, & Rao Ms. (1977). Hepatic Catalase Is Not Essential for the Hypolipidemic Action of Peroxisome Proliferators. Experimental Biology and Medicine. 154(4). 483–487. 13 indexed citations

10.

Crow, James W., et al.. (1977). Glutethimide and 4‐0H glutethimide: Pharmacokinetics and effect on performance in man. Clinical Pharmacology & Therapeutics. 22(4). 458–464. 8 indexed citations

11.

Hignite, Charles E., et al.. (1976). In vitro inhibition of rat liver cholest-5en-3β-ol (cholesterol) biosynthesis by non-mercurial sulfhydryl reagents. Steroids. 27(3). 297–307. 3 indexed citations

12.

Gugler, R, Carl V. Manion, & Daniel L. Azarnoff. (1976). Phenytoin: Pharmacokinetics and bioavailability. Clinical Pharmacology & Therapeutics. 19(2). 135–142. 88 indexed citations

13.

Kauffman, Ralph E., John A. Morris, & Daniel L. Azarnoff. (1975). Placental Transfer and Fetal Urinary Excretion of Gentamicin during Constant Rate Maternal Infusion. Pediatric Research. 9(2). 104–107. 19 indexed citations

14.

Gugler, R, Daniel L. Azarnoff, & Don W. Shoeman. (1975). Diphenylhydantoin: Correlation between protein binding and albumin concentration. Journal of Molecular Medicine. 53(9). 445–446. 25 indexed citations

15.

Shoeman, Don W. & Daniel L. Azarnoff. (1975). Diphenylhydantoin potency and plasma protein binding.. Journal of Pharmacology and Experimental Therapeutics. 195(1). 84–86. 28 indexed citations

16.

Shoeman, Don W., Cesare R. Sirtori, & Daniel L. Azarnoff. (1974). INHIBITION OF AMPHETAMINE TOLERANCE AND METABOLISM BY PROPRANOLOL. Journal of Pharmacology and Experimental Therapeutics. 191(1). 68–71. 6 indexed citations

17.

Huffman, David H., Don W. Shoeman, & Daniel L. Azarnoff. (1974). Correlation of the plasma elimination of antipyrine and the appearance of 4-hydroxy antipyrine in the urine of man. Biochemical Pharmacology. 23(2). 197–201. 63 indexed citations

18.

Wan, Suk Han, Pertti J. Pentikäinen, & Daniel L. Azarnoff. (1974). Bioavailability of Aminosalicylic Acid and Its Various Salts in Humans III: Absorption from Tablets. Journal of Pharmaceutical Sciences. 63(5). 708–711. 21 indexed citations

19.

Sirtori, Cesare R., Per Bolme, & Daniel L. Azarnoff. (1972). Metabolic Responses to Acute and Chronic l -Dopa Administration in Patients with Parkinsonism. New England Journal of Medicine. 287(15). 729–733. 64 indexed citations

20.

Hunninghake, Donald B., et al.. (1969). Long-Term Effects of Clofibrate (Atromid-S) on Serum Lipids in Man. Circulation. 39(5). 675–684. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact